نتایج جستجو برای: activated recombinant factor vii

تعداد نتایج: 1117648  

2015
Christopher E. White Amber E. Schrank

METHODS: Chart review from the trauma registry of a level 1 trauma center between January 1, 2002 and December 31, 2004 identified 2 patients who received rFVIIa for progressive hemorrhagic TBI. These patients were given a single dose of rFVIIa (120 mcg/kg) after a repeat head computed tomography (CT) scan showed worsening of intracranial bleeding. PrerFVIIa and post-rFVIIa coagulation paramete...

2011
Anupama Barua Vinay P Rao BC Ramesh Biplab Barua Hussain El-Shafei

BACKGROUND Refractory post cardiopulmonary bypass (CPB) bleeding continues to cause concern for cardiac surgeons and intensivists. Massive postoperative hemorrhage following CPB is multifactorial and not fully understood, and it is also associated with increased mortality and morbidity. Activated recombinant factor VII (rFVIIa) has emerged as possible salvage medication in refractory post cardi...

2011
D Arora Y Mehta N Trehan

Sarcomatous lesions of the mediastinum usually present as aggressive and multicentre masses often attached to adjoining structures including heart and lungs. A forty one year male diagnosed with sarcomatous lesion in mediastinum presented for biopsy through midsternotomy later confirmed as angiosarcoma on histopathology. Patient bled excessively after surgery and required reopening of the chest...

2007
Sandra Magnetti Karl A. Matuszewski

INTRODUCTION Recombinant activated coagulation factor VII (rFVIIa) is a hemostatic agent developed by Novo Nordisk Pharmaceuticals, Inc., under the trademark NovoSeven. It is a recombinant DNA preparation of a naturally occurring protease, activated blood coagulation factor VII. It is nearly identical to plasmaderived activated factor VII in its pharmacokinetics, structure, and function. The FD...

Journal: :Journal of cardiothoracic and vascular anesthesia 2011
Martin Ponschab Giovanni Landoni Giuseppe Biondi-Zoccai Elena Bignami Elena Frati Davide Nicolotti Fabrizio Monaco Federico Pappalardo Alberto Zangrillo

OBJECTIVES Recombinant activated factor VII (rFVIIa) is used in various surgical procedures to reduce the incidence of major blood loss and the need for re-exploration. Few clinical trials have investigated rFVIIa in cardiac surgery. The authors performed a meta-analysis focusing on the rate of stroke and surgical re-exploration. DESIGN Meta-analysis. SETTING Hospitals. PARTICIPANTS A tot...

Journal: :The Journal of trauma 2005
John B Holcomb

Recombinant activated factor VII (rFVIIa) is a drug commonly utilized in the treatment of patients with hemophilia and inhibitors. However, its use in previously normal patients with an acquired coagulopathy after trauma and surgery is increasing. Multiple trauma case reports and several case series are available, lending support for the efficacy of the drug in reversing the coagulopathy of tra...

Journal: :Critical Care 2006
Thomas Klitgaard Rene Tabanera y Palacios Kenneth D Boffard Philip TC Iau Brian Warren Sandro Rizoli Rolf Rossaint Yoram Kluger Bruno Riou

INTRODUCTION Recombinant activated factor VII (rFVIIa) has been used as adjunctive therapy in trauma patients with severe bleeding. However, its pharmacokinetics profile remains unknown. METHODS In two placebo-controlled studies in patients with blunt and penetrating trauma, the pharmacokinetics of rFVIIa given at an initial dose of 200 microg x kg-1 after transfusion of eight red blood cell ...

Journal: :Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2002
H G D Hendriks K Meijer J Th M de Wolf R J Porte I J Klompmaker H Lip M J H Slooff J van der Meer

Besides the conventional laboratory tests, thromboelastography (TEG) is used to monitor hemostasis during liver transplantation. A previous pilot study suggested a beneficial effect of recombinant activated factor VII (rFVIIa) on transfusion requirements in liver transplantation. In the present study, we assess the effects of rFVIIa on coagulation variables and TEG. In six study patients, the p...

2015
Hesham R. Omar Garrett Enten Rachel Karlnoski Yiu-Hei Ching Devanand Mangar Enrico M. Camporesi

BACKGROUND The off-label use of recombinant activated factor VII (rFVIIa) for intractable bleeding is associated with a risk of thrombotic events. The objective of this study was to evaluate the incidence and predictors of rFVIIa-related thrombotic events and its efficacy in the reduction of transfusion requirements during various surgeries. METHODS Ninety-two cases received rFVIIa for uncont...

Journal: :Current surgery 2006
Christopher E White Amber E Schrank Toney W Baskin John B Holcomb

OBJECTIVE To determine whether treatment with recombinant activated factor VII (rFVIIa) will prevent progression of bleeding in nonsurgical hemorrhagic traumatic brain injury (TBI). METHODS Chart review from the trauma registry of a level 1 trauma center between January 1, 2002 and December 31, 2004 identified 2 patients who received rFVIIa for progressive hemorrhagic TBI. These patients were...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید